Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

M. M. Eggermont, Alexander; U. Blank, Christian; Mandala, Mario; V. Long, Georgina; G. Atkinson, Victoria; Dalle, Stéphane; M. Haydon, Andrew; Meshcheryakov, Andrey; Khattak, Adnan; S. Carlino, Matteo; Sandhu, Shahneen; Larkin, James; Puig, Susana; A. Ascierto, Paolo; Rutkowski, Piotr; Schadendorf, Dirk; Koornstra, Rutger; Hernandez-Aya, Leonel; Maria Di Giacomo, Anna; J. M. van den Eertwegh, Alfonsus; Grob, Jean-Jacques; Gutzmer, Ralf; Jamal, Rahima; C. Lorigan, Paul; C. J. van Akkooi, Alexander; Krepler, Clemens; Ibrahim, Nageatte; Marreaud, Sandrine; Kicinski, Michal; Suciu, Stefan; Robert, Caroline

doi:10.1200/jco.20.02110

Public

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

Shared by NobleBlocks on Nov 20, 2020 • 12:00 AM UTC

Authors:

Alexander M. M. Eggermont

Christian U. Blank

Mario Mandala

Abstract

PURPOSE We conducted the phase III double-blind European Organisation for Research and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial to evaluate pembrolizumab versus placebo in patients with resected high-risk stage III melanoma. On the basis of 351 recurrence-free survival (RFS) events at a 1....

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!